Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25395371 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19307797 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL17062522 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19617896 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL639674 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL1164966 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL19617523 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL1164859 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL22325361 | 0.86 | CHRM2 (0.35) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL20958537 | 0.83 | CHRM2 (0.44) | CHRM2CHRM1CHRM3LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | CHRM2 4685/4885CHRM1 4622/4885CHRM3 4268/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | CHRM2 4685/4885CHRM1 4622/4885CHRM3 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.